 SOUTH SAN FRANCISCO, Calif., Aug. 18, 2020 GLOBE NEWSWIRE -- NGM Biopharmaceuticals, Inc. NGM Nasdaq: NGM, a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announced that comprehensive data from its 24-week Phase 2 study Cohort 4 of aldafermin in patients with non-alcoholic steatohepatitis NASH will be featured in an oral plenary presentation at The Digital International Liver Congress ILC 2020, which will be held virtually August 27-29, 2020.Entitled Positive topline results from a 24-week, placebo-controlled, multicenter, paired liver biopsy study of the FGF19 analogue aldafermin NGM282 in patients with nonalcoholic steatohepatitis, the late-breaker oral presentation LBO-01 will be given by Stephen A. Harrison, M.D., Medical Director at Pinnacle Clinical Research, Visiting Professor of Hepatology at University of Oxford, UK and principal investigator of the study, on Saturday, August 29th at 13:00 13:15 CEST 7:00 7:15 AM ET. The presentation will include detailed findings from the 24-week Phase 2 study as reported by NGM in February 2020, in addition to new analyses from the study.NGM will also have several aldafermin-related poster presentations at Digital ILC 2020, including:Poster THU-200 Abstract title: Veillonella as a bile acid-sensitive bacteria and a microbiome-based biomarker for aldafermin NGM282 in patients with non-alcoholic steatohepatitis Presenting author: Rohit Loomba, M.D., Professor of Medicine in the Division of Gastroenterology at University of California, San Diego Date and time: 8272020, 9:15 19:30 CEST 3:15 AM 1:30 PM ETPoster FRI-258 Abstract title: Aldafermin NGM282 reduces the cross-linked pro-peptides of type III collagen PRO-C3X, a novel biomarker, in nonalcoholic steatohepatitis and primary sclerosing cholangitis patients Presenting author: Stephen A. Harrison, M.D., Medical Director of Pinnacle Clinical Research, Visiting Professor of Hepatology at University of Oxford, UK Date and time: 8282020, 9:30 19:30 CEST 3:30 AM 1:30 PM ETPoster FRI-047 Abstract title: The FGF19 analogue aldafermin NGM282 improves non-invasive tests in patients with nonalcoholic steatohepatitis Presenting author: Marno Ryan, MBBS Hons, M.D., FRACP, Clinical Associate Professor of Medicine, University of Melbourne, Gastroenterologist and Hepatologist, St Vincents Hospital, Melbourne Date and time: 8282020, 9:30 19:30 CEST 3:30 AM 1:30 PM ETPoster FRI-161 Abstract title: Correlation of serum bile acids and pruritus with aldafermin NGM282 therapy in patients with primary sclerosing cholangitis Presenting author: Lei Ling, Ph.D., Director, Clinical Development, NGM Biopharmaceuticals, Inc. Date and time: 8282020, 9:30 19:30 CEST 3:30 AM 1:30 PM ETAll presentations will be available to registered Digital ILC 2020 participants at the meeting website: About NGM Biopharmaceuticals, Inc.NGM is a biopharmaceutical company focused on discovering and developing novel therapeutics based on scientific understanding of key biological pathways underlying liver, retinal and metabolic diseases and cancer. We leverage our biology-centric drug discovery approach to uncover novel mechanisms of action and generate proprietary insights that enable us to move rapidly into proof-of-concept studies and deliver potential first-in-class medicines to patients. At NGM, we aspire to operate one of the most productive research and development engines in the biopharmaceutical industry, with multiple programs in clinical development. Visit us at for more information.Investor Contact: Alex Schwartz Contact: Liz Melone 